Skip to main content

Xarelto: MDL – 2592

Xarelto: MDL – 2592

Xarelto: MDL – 2592

Introduction

Xarelto: MDL No. 2592: in Re: Xarelto Products Liability Litigation, created in January 2017, i is presided by Honorable Eldon E. Fallon, in the U.S. District Court for the Eastern District of Louisiana, where a huge number of Xarelto lawsuits are pending. The Master Case No. 2349 also holds Xarelto cases at the PA Court of Common Pleas in Philadelphia Court of Common Pleas – Complex Litigation (PA State Court). Three verdicts have been announced in favor of the defendants; the fourth verdict initially announced in favor of the plaintiff was tossed in favor of the defendants by the Philadelphia Jury in January 2018. Over 21,000 Xarelto lawsuits are filed nationwide since the New Orleans’ MDL creation.

At the conference meeting held on 30th of January, Judge Fallon urged both parties to arrive at a resolution. To near the end of this MDL, he also made a referral of remanding 1,200 cases back to the court of original jurisdiction for trial or settlement and closing any residual but crucial discovery issues.  

Philadelphia Court of Common Pleas has Xarelto trial dates set for March 19, April 16, and June 11, 2018, to be heard before Judge Arnold New.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

First Federal Bellwether Trial Set in Strattice Mesh Case

Categories: Hernia Mesh

Lawyers involved in federal Strattice hernia mesh litigation are scheduled to meet with the presiding judge in the U.S. District Court for the District of New Jersey to…

Tepezza Hearing Loss Trial Set for June 2026

Categories: Tepezza

The U.S. District Judge overseeing all federal Tepezza lawsuits has postponed the start of the first bellwether trial by 60 days.

This decision comes as attorneys…

FDA Moves to Restrict Dangerous 7-OH Opioid Products

Categories: Opioids

In a significant move to combat the ongoing opioid crisis, the U.S. Food and Drug Administration (FDA) has recommended a scheduling action under the Controlled Substances Act (CSA) to regulate certain products containing 7-hydroxymitragynine (7-…

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!